Nomogram Combined Treatment Data is More Effective than AJCC Staging System for Predicting Overall Survival in GEP-NETs

Researchers conducted a study to develop and validate a nomogram for predicting overall survival (OS) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Using data from the SEER registry, they identified key prognostic factors and compared the nomogram’s performance to the AJCC staging system. The results showed that the nomogram, which combined treatment data, had a higher concordance index and lower AIC values, indicating better discrimination in predicting OS. The nomogram is recommended for evaluating individual risks and improving diagnosis and treatment outcomes for GEP-NETs patients.